Novo Nordisk says it struggling to keep up with demand after becoming Europe’s most valuable company
The maker of blockbuster weight-loss drug semaglutide has reported a steep rise in sales and profits as health systems around the world rush to use it to tackle obesity.
Sales of the Danish pharmaceutical company Novo Nordisk’s diabetes and obesity drugs rose from 113bn Danish kroner (£13.2bn) in the nine months to the end of September 2022 to 154bn kroner for the same period in 2023.
Continue reading…
Source: The Guardian